IRCT201112265110N2已完成2 期
Evaluation of the Effect of Human Recombinant Erythropoietin on Reducing Need to Blood Transfusion in Very-Low-Birth-Weight Infants
Vice Chancellor for Research and Tchnology, Hamadan University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 years 至 28 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria: Neonates with birth weight less than 1500 gram; gestational age less than 31 weeks; post natal age at Least 6 days; received calories at least 50 Kcal/kg, at Least 50% in enteral route; Hct=< 40%. Exclusion criteria: Severe congenital anomalies, dysmorphic syndromes; hemolytic anemia; severe acute infections.
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Effects of Recombinant Human Erythropoietin on Patient Survival Rate during Severe SepsisSepsis AnemiaErythropoietinSurvival rateSepsisTCTR20201022004one300
尚未招募
1 期
iorEPOCIM-Stroke-Phase IStrokeRPCEC00000136Center of Molecular Inmunology (CIM)20
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338
暂停
1 期
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I.Acute Cerebral Ischemic Stroke.RPCEC00000078Center of Molecular Inmunology(CIM)20
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60